No price history available.
Key financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | IDRm | 294,917 | 435,196 | 359,156 | 373,400 | 441,072 | 469,593 | N/A | N/A |
| Operating profit | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | IDRm | 2,616 | 52,909 | 26,180 | 25,189 | 39,692 | 34,507 | N/A | N/A |
| EPS reported | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
PT Kedoya Adyaraya Tbk operates as an Indonesian healthcare enterprise, managing and owning hospitals throughout the country. The company delivers a broad spectrum of medical services across numerous specialties, encompassing comprehensive surgical procedures such as general, orthopedic, urological, cardiothoracic, plastic, and neurological operations. It also provides internal medicine subspecialties like nephrology, endocrinology, and general internal medicine, alongside care in obstetrics and gynecology, cardiology, neurology, pulmonology, ophthalmology, hyperbaric medicine, and pediatrics. Additional services include acupuncture, medical rehabilitation, and speech therapy. Oral health is addressed through oral and maxillofacial services, prosthodontics, and general dentistry. Furthermore, mental health support is provided by psychiatrists and psychologists, nutritional guidance by dietitians, and specialized treatment for skin and venereal conditions. Beyond these specialized areas, the company also offers general medical care. As of December 31, 2021, PT Kedoya Adyaraya Tbk operated two hospitals, offering a combined capacity of 200 patient beds. Established in 1990, the company's main office is located in Jakarta Barat, Indonesia, and it functions as a subsidiary of PT Sarana Meditama Metropolitan Tbk.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
PT Kedoya Adyaraya Tbk operates as an Indonesian healthcare enterprise, managing and owning hospitals throughout the country. The company delivers a broad spectrum of medical services across numerous specialties, encompassing comprehensive surgical procedures such as general, orthopedic, urological, cardiothoracic, plastic, and neurological operations. It also provides internal medicine subspecialties like nephrology, endocrinology, and general internal medicine, alongside care in obstetrics and gynecology, cardiology, neurology, pulmonology, ophthalmology, hyperbaric medicine, and pediatrics. Additional services include acupuncture, medical rehabilitation, and speech therapy. Oral health is addressed through oral and maxillofacial services, prosthodontics, and general dentistry. Furthermore, mental health support is provided by psychiatrists and psychologists, nutritional guidance by dietitians, and specialized treatment for skin and venereal conditions. Beyond these specialized areas, the company also offers general medical care. As of December 31, 2021, PT Kedoya Adyaraya Tbk operated two hospitals, offering a combined capacity of 200 patient beds. Established in 1990, the company's main office is located in Jakarta Barat, Indonesia, and it functions as a subsidiary of PT Sarana Meditama Metropolitan Tbk.